Return to Resource Center > Communications and Media

2010 West Nile Virus Workshop Presentations

Ritz Carlton Tysons Corner
1700 Tysons Boulevard
McLean, Virginia 22102

Friday, July 9, 2010

8:30 AM - 8:40 AM        
Welcome
P. Robert Rigney, Jr., Esq., Chief Executive Officer, American Association of Tissue Banks

8:40 AM - 9:10 AM        
FDA and Regulation of Human Cells, Tissues, and Cellular and Tissue-based Products (HCT/Ps)
Melissa Greenwald, MD, Chief of the Reproductive and Human Tissue Branch, Division of Human Tissues, OCTGT/CBER/FDA

9:25 AM - 10:05 AM      
Overview of West Nile Virus (WNV)
J. Erin Staples, MD, PhD, Medical Epidemiologist, CDC at Ft. Collins, CO
Mike Drebot, PhD, Chief, Viral Zoonoses & Research Coordination: H1N1 Studies; Director, Science Technology and Core Services, National Microbiology Laboratory, Public Health Agency of Canada (PHAC)

10:40 AM - 11:10 AM    
Review of Reported Cases of WNV Transmission
Matt Kuehnert, MD, Director, Office of Blood, Organ, and Other Tissue Safety, CDC

11:10 AM - 11:30 AM    
Recipient Demographics and Risk Considerations
Marian G. Michaels, MD, MPH, Professor of Pediatrics and Surgery, Children's Hospital of Pittsburgh, Division of Infectious Diseases

1:00 PM - 1:45 PM        
Experiences Using WNV NAT
Jerry Niedzinski, BS, CHS, Senior Scientist, LABS, Inc.
Karen Norman, Executive Director of Quality Assurance, RTI Biologics, Inc.
Maria Rios, PhD, Research Biologist, FDA/CBER/OBRR

2:00 PM - 2:20 PM        
Testing Human and Non-Human Animal Tissue
Robert Lanciotti, PhD, Chief, Diagnostic & Reference Laboratory, Arbovirus Disease Branch, CDC, Ft. Collins, CO

2:35 PM - 3:20 PM        
Tissue Handling and Processing Studies
Alyce Linthurst-Jones, PhD, RAC, Project Manager, LifeNet Health
Carrie Hartill, Chief Scientific Officer and Vice President, Quality Assurance & Regulatory Affairs, RTI Biologics
Mary Malarkey, Director, Office of Compliance and Biologics Quality (OCBQ), FDA

4:00 PM - 5:00 PM        
What are the Scientific Considerations for Tissue Donors and What Research Could be Performed to address those considerations?
Harvey J. Stern, MD, PhD, Medical Director, Fairfax Cryobank, division of Genetics & IVF Institute (reproductive tissue representative)
Bruce Bodner, MD, Medical Director, Lions Medical Eye Bank (EBAA representative)
Michael Ison, MD, MS, Chair, UNOS Disease Transmission Advisory Group, AST Executive Committee for Infectious Diseases Study Group
Jerry Holmberg, PhD, MT (ASCP) SBB, Senior Advisor to the Secretary of HHS, Advisory Committee on Blood Safety & Availability
Lyle Peterson, MD, MPH, Director, Division of Vector-Borne Diseases, CDC
Francisca Agbanyo, PhD, Chief, Blood, Cells, Tissues, Organs and Xenografts Division Centre for Blood and Tissue Evaluation Biologics and Genetic Therapies Directorate, Health Products and Food Branch, Health Canada
Celia Witten, PhD, MD, Director, Office of Cellular, Tissue, and Gene Therapy, CBER/FDA
David Gocke, MD, Medical Director, Musculoskeletal Transplant Foundation
Greg Ray, MD, FCAP, Medical Director, CryoLife, Inc